{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:22:31Z","timestamp":1775168551960,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Alveolar soft part sarcoma (ASPS) is a rare sarcoma that has been shown to be highly effective to antiangiogenic agents and immune checkpoint inhibitors, but most reported studies about ASPS were concentrated on adult population. In this study, we aimed to describe the clinical features and therapeutic outcomes of ASPS in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed the records of patients with ASPS in our institution since Jan 2015. All patients included in this study were pathologically confirmed ASPS and aged under 12 years at the time of initial diagnosis. Demographic characteristics, tumor sizes, primary tumor sites, metastasis, treatments used, therapeutic responses and survivals were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified a total of 56 patients to be initially diagnosed as ASPS since Jan 2015.\u00a0A predisposition of high occurrence in head and neck (32.1%) was observed (versus 41.1% in limbs and 21.4% in trunk). 26 (46.4%) patients developed metastasis at the time of diagnosis or during follow-up. Tumors in tongue, pharynx and larynx had the least likelihood to metastasize (7.7%, P&amp;lt;0.05). Observation was recommended for 15 stage IV patients with only pulmonary metastasis. 7 (46.7%) patients remained stable until last follow up. The 1-year PFS rate was 83.3% and median progression-free survival time (PFS) was 29.4 months. 15 patients with progressive disease received mono or combined therapy. 11 patients received PD-1 monotherapy. 2 patients achieved partial response and 5 stable disease. The overall response rate was 18.2%. The median PFS of this group was 22.0 months, and the 1-year PFS rate was 70.0%. 4 patients received a combination therapy of PD-1 inhibitors plus tyrosine kinase inhibitors. All of them remained stable. No disease-related death occurred during follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ASPS exhibits a higher occurrence in head and neck in children. ASPS originating from glossopharyngeal region tends to have a lower metastasis rate. ASPS displays a more indolent growth pattern in children, which makes observation a preferable choice for children with sole pulmonary metastasis. Pediatric ASPS appears to be less effective to targeted therapy and immunotherapy than adults. The treatment of progressive ASPS in children remains challenging.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1019911","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T08:57:45Z","timestamp":1669280265000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical features and therapeutic outcomes of alveolar soft part sarcoma in children: A single-center, retrospective study"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhichao","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifeng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengfu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chujie","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2005.031120","article-title":"Alveolar soft-part sarcoma: a review and update","volume":"59","author":"Folpe","year":"2006","journal-title":"J Clin Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890101)63:1<1::AID-CNCR2820630102>3.0.CO;2-E","article-title":"Alveolar soft-part sarcoma. a clinico-pathologic study of half a century","volume":"63","author":"Lieberman","year":"1989","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1038\/modpathol.2013.83","article-title":"Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases","volume":"27","author":"Hodge","year":"2014","journal-title":"Mod Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.053","article-title":"Adult-type soft tissue sarcomas in pediatric-age patients: experience at the istituto nazionale tumori in Milan","volume":"23","author":"Ferrari","year":"2005","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2020.06.007","article-title":"Characterization of alveolar soft part sarcoma using a large national database","volume":"168","author":"Hagerty","year":"2020","journal-title":"Surgery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00264-8","article-title":"Chemotherapy in alveolar soft part sarcomas. what do we know","volume":"39","author":"Reichardt","year":"2003","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.04.034","article-title":"Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis","volume":"152","author":"Saerens","year":"2021","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30215-3","article-title":"Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial","volume":"20","author":"Judson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14542","article-title":"Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese musculoskeletal oncology group study","volume":"111","author":"Urakawa","year":"2020","journal-title":"Cancer Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0871","article-title":"Phase II study of TQB2450, a novel PD-L1 antibody, in combination with anlotinib in patients with locally advanced or metastatic soft tissue sarcoma","author":"Liu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24683","article-title":"Paediatric and adolescent alveolar soft part sarcoma: A joint series from European cooperative groups","volume":"60","author":"Orbach","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26953","article-title":"Alveolar soft part sarcoma in children and young adults: A report of 69 cases","volume":"65","author":"Flores","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026579623136","article-title":"Alveolar soft part sarcoma in children and adolescents: A report from the soft-tissue sarcoma Italian cooperative group","volume":"11","author":"Casanova","year":"2000","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt126","article-title":"Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution","volume":"24","author":"Mattavelli","year":"2013","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000815)89:4<868::AID-CNCR20>3.0.CO;2-9","article-title":"Prognostic factors in head and neck soft tissue sarcomas","volume":"89","author":"Dudhat","year":"2000","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19920701)70:1<169::AID-CNCR2820700127>3.0.CO;2-F","article-title":"Sarcomas of the head and neck. prognostic factors and treatment strategies","volume":"70","author":"Tran","year":"1992","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4490","article-title":"Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: A review","volume":"5","author":"Paoluzzi","year":"2019","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.11519","article-title":"Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS)","volume":"39","author":"Naqash","year":"2021","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.01.028","article-title":"Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study","volume":"130","author":"Yang","year":"2020","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: A single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0697-6","article-title":"Does patient age influence anti-cancer immunity","volume":"41","author":"Pawelec","year":"2019","journal-title":"Semin Immunopathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1019911\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T08:57:49Z","timestamp":1669280269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1019911\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":21,"alternative-id":["10.3389\/fonc.2022.1019911"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1019911","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"article-number":"1019911"}}